These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 26400847)

  • 1. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
    Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
    Breast Cancer Res Treat; 2015 Oct; 153(3):493-505. PubMed ID: 26400847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.
    Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
    Pharmacogenomics; 2015; 16(12):1411-26. PubMed ID: 26257318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
    de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
    Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.
    Elster N; Collins DM; Toomey S; Crown J; Eustace AJ; Hennessy BT
    Breast Cancer Res Treat; 2015 Jan; 149(1):5-15. PubMed ID: 25542271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Evolving Landscape of HER2 Targeting in Breast Cancer.
    Moasser MM; Krop IE
    JAMA Oncol; 2015 Nov; 1(8):1154-61. PubMed ID: 26204261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.
    Monteiro Ide P; Madureira P; de Vasconscelos A; Pozza DH; de Mello RA
    Pharmacogenomics; 2015; 16(3):257-71. PubMed ID: 25712189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Spector NL; Blackwell KL
    J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
    J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
    Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer.
    Menyhárt O; Santarpia L; Győrffy B
    Curr Cancer Drug Targets; 2015; 15(8):665-83. PubMed ID: 26452383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
    Creedon H; Byron A; Main J; Hayward L; Klinowska T; Brunton VG
    Biochem Soc Trans; 2014 Aug; 42(4):822-30. PubMed ID: 25109964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of phosphorylated HER2 with clinicopathological characteristics and efficacy of trastuzumab treatment for breast cancer.
    Ramić S; Asić K; Balja MP; Paić F; Benković V; Knežević F
    Anticancer Res; 2013 Jun; 33(6):2509-15. PubMed ID: 23749902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?
    Zelnak AB; Wisinski KB
    Cancer; 2015 Jan; 121(1):17-24. PubMed ID: 25056442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.
    Rexer BN; Arteaga CL
    Crit Rev Oncog; 2012; 17(1):1-16. PubMed ID: 22471661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-directed therapy for metastatic breast cancer.
    Jelovac D; Emens LA
    Oncology (Williston Park); 2013 Mar; 27(3):166-75. PubMed ID: 23687784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.